Search

Displaying results 2661 - 2670 of 2955 in total
  1. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously

  2. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

  3. Drug

    AK106-001616

    go.drugbank.com/drugs/DB16058
    Investigational

    AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

  4. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  5. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram.

  6. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    A18564,A174934] Compared to available long-acting analogs such as [DB00047] and [DB01307], which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over … [A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus.

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for Injection
  7. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.

  8. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    (FDA) of the United States. … These pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration

    Synonyms: (E)-Nerol, (E)-Geraniol
  9. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

  10. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017.